Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Advinus collaborates with Corning to bring Epic technology to India

Advinus Therapeutics, the research-based pharmaceutical company promoted by the TATA Group, and Corning Incorporated today announced a collaboration to bring Corning Epic label-free detection technology to India.

2 Dec 2010

NHS to develop new treatment options for patients with lung disease

Scientists and clinicians in Nottingham are to work more closely with industry to develop new ways of diagnosing and treating lung disease.

2 Dec 2010

PepTcell changes name to SEEK

PepTcell, a leading UK privately-owned drug-discovery group, today announced it is changing its name to SEEK.

1 Dec 2010

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that initial safety and efficacy data from its ongoing Phase II Study with resminostat, a pan-Histone Deacetylase (HDAC) Inhibitor, in relapsed/refractory Hodgkin Lymphoma (HL) patients after high dose chemotherapy and autologous hematopoietic stem cell transplantation will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, USA.

1 Dec 2010

Scripps Research Institute enters agreement with Aileron Therapeutics

The Scripps Research Institute and Aileron Therapeutics today announced that they have entered into an agreement that will add Scripps Research's "Click" chemistry to Aileron's proprietary stabilized peptide and protein technology platforms, which includes the Stapled Peptide technology.

1 Dec 2010

Anacor, UCSF and NYBC collaborate to discover drug therapies for river blindness

Anacor Pharmaceuticals, the University of California San Francisco (UCSF) Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center (NYBC) today announced the establishment of a research and development collaboration to discover new drug therapies for the treatment of river blindness (onchocerciasis), a parasitic disease that is the second leading cause of infectious blindness worldwide, and is most prevalent in Africa.

1 Dec 2010

USC purchases WaferGen SmartChip system for Molecular Pathways and Drug Discovery center

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced that the University of Southern California (USC) has purchased the WaferGen SmartChip system for its USC Center for Molecular Pathways and Drug Discovery to discover and validate biomarkers for pancreatic and colorectal cancer applications to expedite the development of a cancer therapy. USC purchased a solution that includes the SmartChip platform and validated gene panels for biomarker profiling.

1 Dec 2010

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Neuroscientists using a new brain imaging technique could see an investigational drug for Parkinson's disease get into a patient's brain and affect blood flow in several key structures, an indicator the drug may be effective.

1 Dec 2010

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Aphios® Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for Developing a Novel Alzheimer's Disease Nanodrug.

30 Nov 2010

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.

30 Nov 2010

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

Quintiles, the world's leading biopharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.

30 Nov 2010

New 'canSAR' cancer drug discovery database launched

A powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from 'bench to bedside'.

29 Nov 2010

Marcus evans Summit highlights potential growth, innovation in drug discovery

Drug discovery scientists need to broaden their approaches to pharmaceutical research and development (R&D) and Medicinal Chemistry, to take advantage of untapped opportunities, says Torsten Hoffmann, Head Discovery Chemistry at F. Hoffmann La Roche, Basel, Switzerland. Chemical Biology allows room for innovation, but is often overlooked by scientists in the industry.

29 Nov 2010

Selcia announces drug discovery collaboration agreement with Gilead Sciences

Selcia Limited, a leading contract research organisation, today announced a drug discovery collaboration agreement with Gilead Sciences, Inc. (Foster City, California).

29 Nov 2010

Thomson Reuters announces acquisition of GeneGo

Thomson Reuters today announced that it has acquired GeneGo, a leading provider of biology and disease information, analytics, and decision support solutions for pharmaceutical research and development.

29 Nov 2010

New irreversible covalent approach to inhibit viral protease

28 Nov 2010

CQDM and Alsace BioValley enter long term research collaboration

Alsace BioValley, a French competitive health cluster dedicated to therapeutic innovation and CQDM (Québec Consortium for Drug Discovery) sign in Paris today an agreement on a bilateral partnership for the benefit of Alsatian and Quebec research centers and industries in the life sciences and health sector.

26 Nov 2010

RCSI review highlights development in drug discovery field

A research review carried out by the Royal College of Surgeons in Ireland (RCSI) and published in 'Nature Reviews and Drug Discovery' (October 2010) has highlighted the lessons, opportunities and recent developments in the area of drug development for cardiovascular disease, auto-immune disorders and multiple sclerosis.

25 Nov 2010

Amorfix introduces high affinity antibodies against cancer primary cells

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that together with its partner Epitomics, high affinity antibodies to prion protein disease specific epitopes (DSEs) have been produced, which bind preferentially to several cancer primary cells and tumor cell lines, but not normal cells.

24 Nov 2010

Evotec to collaborate with Merck on neurological disease drug discovery program

Evotec AG today announced that it has signed within the "NEU²-Consortium" framework and partially funded by the Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung - BMBF), an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease. Evotec will provide drug discovery expertise covering in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology.

23 Nov 2010

Drug Discovery News and Research

Further Reading

Advinus collaborates with Corning to bring Epic technology to India

NHS to develop new treatment options for patients with lung disease

PepTcell changes name to SEEK

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

Scripps Research Institute enters agreement with Aileron Therapeutics

Anacor, UCSF and NYBC collaborate to discover drug therapies for river blindness

USC purchases WaferGen SmartChip system for Molecular Pathways and Drug Discovery center

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

New 'canSAR' cancer drug discovery database launched

Marcus evans Summit highlights potential growth, innovation in drug discovery

Selcia announces drug discovery collaboration agreement with Gilead Sciences

Thomson Reuters announces acquisition of GeneGo

New irreversible covalent approach to inhibit viral protease

CQDM and Alsace BioValley enter long term research collaboration

RCSI review highlights development in drug discovery field

Amorfix introduces high affinity antibodies against cancer primary cells

Evotec to collaborate with Merck on neurological disease drug discovery program

Drug Discovery - Second Edition eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News